HUTCHMED - News & Press Releases

2009年7月29日，和黄医药宣布提前完成了HMPL-004治疗轻中度活动期溃疡性结肠炎的全球IIb期临床试验患者的招募。IIb期临床试验是为了进一步证实候选药物HMPL-004在较大样本的人群和不同剂量�

Notice of Announcement of 2010 Final Results

Total Voting Rights

Blocklisting Six Monthly Return

Hutchison MediPharma Receives Further Strategic Investment to Advance Its Pipeline

China Healthcare Division Chi-Med increases indirect ownership of its Hutchison Baiyunshan joint venture

Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine (Alimentary Pharmacology and Therapeutics 2011)

Hutchison MediPharma Receives Strategic Investment to Advance Its Pipeline

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor

Hutchison Hain Organic launch EARTH'S BEST® and ZHI LING TONG Co-branded Infant formula in China

Appointment of Joint Broker

Interim Results for the Six Months Ended 30 June 2010 Strong results. Continued momentum. Positive outlook.

TR-1: Notification of major interests in shares

Notice of Announcement of 2010 Interim Results

TR-1: Notification of major interests in shares

Total Voting Rights

Blocklisting Six Monthly Return

Director's Shareholding

TR-1: Notification of major interests in shares

和黄医药抗癌新药索凡替尼获得国家药监局新药临床试验批文

Results of Annual General Meeting

Seven-year extension of IP protection for Chi-Med's main prescription drug

2009 Annual Report and Notice of Annual General Meeting

TR-1: Notification of major interests in shares

TR-1: Notification of major interests in shares

TR-1: Notification of major interests in shares

TR-1: Notification of Major Interests in Shares

Final Results for the year ended 31 December 2009

Notice of Announcement of 2009 Final Results

Total Voting Rights

Three more of Chi-Med's China Healthcare Division drugs added to latest China's National Medicines Catalogue

Total Voting Rights

Blocklisting Six Monthly Return

TR-1 : Notification of Major Interests in Shares

Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved Hutchison MediPharma Proceeding with Development and Partnership Plans

和黄医药（上海）有限公司启动治疗自身免疫病的全新侯选药物HMPL-011的一期临床试验

Chi-Med increases ownership of its Hutchison Healthcare joint venture to 100%

Newly Published China National Essential Medicines List Reference Prices No Overall Negative Impact on Chi-Med Prices

Chi-Med announces joint venture with The Hain Celestial Group to develop natural and organic consumer products in Asia

Chi-Med's Main Drugs Included in the New National Essential Medicines List

Interim Results for the Six Months Ended 30 June 2009

和黄医药提前完成了治疗溃疡性结肠炎的候选药物（HMPL-004）全球IIb期临床试验患者的招募

和黄医药宣布HMPL-004治疗克罗恩病的国际多中心II期临床试验结果

Notice of Announcement of 2009 Interim Results

Blocklisting Six Monthly Return

Results of Annual General Meeting

Director's Shareholding

2008 Annual Report and Notice of Annual General Meeting

TR-1: Notification of major interests in shares

TR-1: Notification of major interests in shares

Date of Annual General Meeting